www.BillionPhotos.com / Shutterstock.com
17 December 2015Generics

Purdue hits Alvogen with ANDA lawsuit

Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.

Butrans is a skin patch, which is used to treat chronic pain. It is marketed in dosages of 5, 10 and 20mcg.

In October, Alvogen filed an Abbreviated New Drug Application (ANDA) which sought permission to market a generic version of Butrans.

Upon being informed of the ANDA, Purdue filed a lawsuit at the US District Court for the District of Delaware, alleging infringement of three of its US registered patents.

“Defendant has committed, or aided, abetted, contributed to, and/or participated in the commission of, the tortuous act of patent infringement that has led to foreseeable harm and injury to Purdue”, claimed Purdue in a lawsuit filed on November 20.

Purdue is requesting that the district court rules the case is exceptional and award it its legal costs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk